Commentary|Videos|April 30, 2025
How ctDNA Is Informing Ongoing Trials in CRC
Author(s)Scott Kopetz, MD, PhD, FACP, Mark A. Lewis, MD
Fact checked by: Chris Ryan
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss ongoing research in CRC utilizing ctDNA.
Advertisement
Episodes in this series
Advertisement
Related to this article
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
2
CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease
3
FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test
4
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
5